$PXMD - PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission

In a groundbreaking presentation at the American Association for Cancer Research (AACR) Annual Meeting, Indaptus Therapeutics Inc. (NASDAQ: INDP) has shared promising data that could potentially revolutionize the way we approach cancer treatment. Their research focuses on the Decoy bacteria technology, an innovative method designed to prime the immune system both directly and indirectly, thereby enhancing its ability to effectively combat cancer. $Indaptus Therapeutics(INDP.US)$